[go: up one dir, main page]

Olive, 2005 - Google Patents

mGlu5 receptors: neuroanatomy, pharmacology, and role in drug addiction

Olive, 2005

Document ID
9366836576632176814
Author
Olive M
Publication year
Publication venue
Current Psychiatry Reviews

External Links

Snippet

Over the past half century, most studies investigating the neural substrates of drug addiction have focused on the mesolimbic dopamine reward circuitry. Yet recent evidence suggests a critical role for glutamate neurotransmission in addiction-related behaviors. Glutamate …
Continue reading at www.ingentaconnect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure

Similar Documents

Publication Publication Date Title
Darcq et al. Opioid receptors: drivers to addiction?
Martina et al. Glycine transporter type 1 blockade changes NMDA receptor‐mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels
Cahill et al. Convergence of dopamine and glutamate signaling onto striatal ERK activation in response to drugs of abuse
Bettler et al. Molecular structure and physiological functions of GABAB receptors
Szumlinski et al. Homers regulate drug-induced neuroplasticity: implications for addiction
Schmid et al. Physiological and pharmacological implications of beta-arrestin regulation
Haas et al. Histamine in the nervous system
Plaza-Zabala et al. The hypocretin/orexin system: implications for drug reward and relapse
Sim-Selley Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids
Fienberg et al. The DARPP-32 knockout mouse
Ting-A-Kee et al. The neurobiology of opiate motivation
Crabbe et al. Alcohol‐related genes: contributions from studies with genetically engineered mice
Lee et al. Protein kinases and addiction
Hack et al. Adaptations in adenosine signaling in drug dependence: therapeutic implications
Iasevoli et al. The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment
Yamada et al. Novel insights into M5 muscarinic acetylcholine receptor function by the use of gene targeting technology
Romanelli et al. Dopamine receptor signaling: intracellular pathways to behavior
Castané et al. Attenuation of nicotine-induced rewarding effects in A2A knockout mice
Malcangio et al. Possible therapeutic application of GABAB receptor agonists and antagonists
Marino et al. Targeting the metabotropic glutamate receptor mGluR4 for the treatment of diseases of the central nervous system
Olive mGlu5 receptors: neuroanatomy, pharmacology, and role in drug addiction
Ding et al. Involvement of local serotonin-2A but not serotonin-1B receptors in the reinforcing effects of ethanol within the posterior ventral tegmental area of female Wistar rats
Ferraro et al. The new compound GET73, N-[(4-trifluoromethyl) benzyl] 4-methoxybutyramide, Regulates hippocampal Aminoacidergic transmission possibly via an allosteric modulation of mGlu5 receptor. Behavioural evidence of its “anti-alcohol” and anxiolytic properties
Ledonne et al. Trace amines depress D2‐autoreceptor‐mediated responses on midbrain dopaminergic cells
Green et al. The effects of electroconvulsive therapy and antidepressant drugs on monoamine receptors in rodent brain—similarities and differences